Epigenic Therapeutics to Enter Clinical Development of EPI-003: A First-in-Class Epigenetic Inactivator for the Treatment of Chronic Hepatitis B

Posted on by

SHANGHAI, Nov. 19, 2024 /PRNewswire/ — Epigenic Therapeutics, a leading biotechnology company dedicated to developing next-generation gene modulation therapy, today announced that it has received approval of clinical trial application (CTA) from the New Zealand Medicines and Medical…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.